Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine with or without dalteparin for advanced pancreatic adenocarcinoma
ISRCTN76464767Phase 2Completed
- Sponsor
- United States Department of Health and Human Services
- Start
- Jan 2003
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Gemcitabine alone with Gemcitabine + dalteparin (2 arms). Primary endpoint: Incidence of venous thromboembolism reduction. Started Jan 2003; status: completed.
02
Drugs
gemcitabinedalteparin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN76464767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN76464767.